44 results about "Vascular calcification" patented technology

The invention provides a vascular calcification analysis method and device based on a non-enhanced CT image, and relates to the technical field of artificial intelligence. The method comprises the following steps: analyzing scanning parameter information of a non-contrast enhanced scanning image set; standardizing the non-contrast enhanced scanning image set based on the scanning parameter information to obtain a preprocessed image sequence; inputting the preprocessed image sequence into a multi-modal registration network, and generating a fused image based on the obtained key anatomical mark points; inputting the fused image into an attention-enhanced segmentation network, and determining blood vessel segmentation masks of the thoracic aorta, the common carotid artery and the intracranial artery; a candidate voxel set is extracted from the fused image based on the blood vessel segmentation mask, three-dimensional connected domain analysis is carried out on the candidate voxel set, and a blood vessel calcification three-dimensional area is determined; and inputting the vascular calcification three-dimensional region into the multi-task prediction model, determining a quantitative score of the vascular calcification degree, and improving the accuracy and reliability of a vascular calcification evaluation result.

The invention discloses an intelligent image detection system for dynamically monitoring vascular calcification of diabetes, and belongs to the technical field of medical images and intelligent diagnosis and treatment. Comprising a multi-modal image acquisition module, a cross-modal data processing module, a dynamic modeling and intelligent prediction module and a closed-loop intervention module. According to the invention, through multi-modal data acquisition and processing, integration and analysis of data from different sources are realized, so that characteristics and change rules of diabetic vascular calcification can be better known. And secondly, by utilizing a dynamic modeling and intelligent prediction module, simulation and prediction of the diabetes vascular calcification process can be realized, and making of personalized diagnosis and treatment plans and intervention measures is facilitated. And finally, the closed-loop intervention module can adjust a treatment scheme in real time according to a monitoring result so as to achieve a better treatment effect. Accurate dynamic monitoring and closed-loop intervention of diabetic vascular calcification are achieved, and the method has the advantages of intelligent switching of detection modes, deep fusion of multi-modal data, dynamic optimization of treatment schemes and the like.

The invention relates to a vascular calcification degree determination method and device, computer equipment, a storage medium and a computer program product. The method comprises the following steps: acquiring an image frame sequence containing a plurality of image frames; an image segmentation model is adopted to segment the plurality of image frames, image segmentation results corresponding to the plurality of image frames are obtained, and each image segmentation result comprises an intima segmentation area and a calcification segmentation area; the image segmentation model is obtained through training based on sample coding images corresponding to a plurality of sample image frames; each sample coding image is obtained by coding the current sample image frame according to a plurality of previous sample image frames and a plurality of later sample image frames of the corresponding current sample image frame; and determining the vascular calcification degree according to the intimal segmentation areas and the calcification segmentation areas corresponding to the plurality of image frames. By adopting the method, the accuracy of the determined vascular calcification degree can be improved.

The invention discloses a marker for diagnosing artery blood vessel calcification, a kit and application, and belongs to the technical field of biomedicine. The peripheral blood miR-221-3p disclosed by the invention is a biomarker with a specific screening value for vascular calcification, the peripheral blood miR-221-3p can be used for diagnosing a patient with vascular calcification by detecting the miR-221-3p, the AUC value of the miR-221-3p for diagnosing vascular calcification is 0.742, the sensitivity is 73.3%, and the specificity is 85.0%, so that the miR-221-3p as the biomarker has a relatively high diagnostic value for vascular calcification. Through development and application of the peripheral blood marker miR-221-3p related to vascular calcification and the diagnostic kit, the vascular calcification condition can be rapidly diagnosed and effectively treated in time, and a scientific basis is provided for exploring a novel and effective small molecule drug target.

A consumable management system and management method and a vascular calcification treatment device. The consumable management system includes a control circuit (100) and a consumable circuit (200); the control circuit (100) includes a processing module (110), a first power supply module (120), and a second power supply module (130); the consumable circuit (200) includes a fusing module (210); when the state of the fusing module (210) is determined to be a connected state, the processing module (110) outputs a fusing trigger signal to the second power supply module (130); the first power supply module (120) is configured to output a first power supply signal to the fusing module (210) for state detection of the fusing module (210); the second power supply module (130) is configured to enable the fusing module (210) to be in a disconnected state. The present invention is high in stability and low in cost.

Use of 1-methylnicotinamide in preparation of an anti-vascular calcification drug. It is found that the small molecule metabolite 1-methylnicotinamide has an effect of inhibiting vascular calcification and its progress, which provides a new idea for treatment of vascular calcification. Moreover, 1-methylnicotinamide has good drug safety and a strong vascular calcification inhibition effect, and can be used as a candidate drug for inhibiting vascular calcification. In addition, 1-methylnicotinamide is a known small molecule metabolite that is soluble in water or DMSO, has good stability, low cytotoxicity and good drug safety, and can be flexibly administrated in various modes such as oral administration and intravenous injection.

The invention relates to an application of loratadine in preparation of drugs for preventing and treating vascular calcification. The structural formula of the loratadine is as follows: # imgabs0. The loratadine used in the invention can significantly reduce the level of mouse aortic vascular calcification, and the experimental result proves that the loratadine has the effects of preventing and treating vascular calcification. The medicine disclosed by the invention is relatively low in toxicity and relatively high in safety.

The invention discloses a shock wave balloon catheter, and belongs to the technical field of medical equipment, the shock wave balloon catheter comprises an inner-layer catheter, an electrode assembly and an outer-layer balloon assembly, the inner-layer catheter is provided with a working section, the electrode assembly and the outer-layer balloon assembly are both installed on the working section, the outer-layer balloon assembly comprises an outer-layer balloon and a blocking part, and the blocking part is arranged on the outer-layer balloon. The outer-layer balloon wraps the electrode assembly, the blocking part is provided with an expansion area capable of being folded and unfolded in the radial direction of the working section, and the blocking part can block the inner-layer catheter from moving in the radial direction after the expansion area is unfolded, so that a safe distance is formed between the electrode assembly and the outer-layer balloon. After the expansion area expands in the radial direction, a safe distance can be formed between the electrode assembly and the outer-layer balloon, and therefore it can be guaranteed that a certain safe distance is always formed between the electrode assembly and the blood vessel wall, the eccentric degree of the electrode assembly is reduced, the circumferential uniformity of the electrode assembly for treating the vascular calcification lesion position is improved, and the blood vessel is prevented from being damaged.

The invention discloses a method and device for determining a gray value of a specific area of a detected object, a computer program, a computer readable storage medium and medical imaging equipment. The method for determining the gray value of the specific area of the examined object comprises the following steps: carrying out tomography on a correction die body on an examination bed; storing a cross-sectional image of the correction die body; performing tomography on the detected object; and according to the cross-sectional image of the correction die body and the cross-sectional image of the detected object, determining a gray value of a specific area of the detected object. According to the method, the workflow can be simplified, and the volume bone mineral density which is high in accuracy and not affected by height, weight, spinal hyperplasia, degeneration and vascular calcification is provided with low dosage.

A biological nanoparticle for targeted therapeutic delivery is provided. The biological nanoparticle includes a plurality of extracellular vesicles. Characteristically, each extracellular vesicle contains a microRNA, which has been modified with ExoMotif sequences to enhance selective loading into the vesicles during their biogenesis. The microRNA is configured to inhibit plaque formation and vascular calcification. Additionally, a hydroxyapatite-binding peptide (HABP) is conjugated to the surface of each extracellular vesicle, facilitating targeted delivery to calcified tissues. This configuration enables the nanoparticle to specifically target areas of vascular calcification, where it can deliver the microRNA to modulate cellular behavior.

The present invention relates to a pharmaceutical composition containing Cbfβ (Core-binding factor subunit beta) expressing vascular smooth muscle cells or a culture fluid thereof as an active ingredient for the prevention or treatment of age-related diseases. It has been found that inhibition of Cbfβ expression in vascular smooth muscle cells promotes vascular calcification and osteoclast differentiation and that the culture fluid of Cbfβ-expressing vascular smooth muscle cells inhibits osteoclast differentiation. Thus, the composition can be advantageously utilized as a pharmaceutical composition for the prevention, treatment, alleviation, or diagnosis of age-related diseases.

The invention belongs to the technical field of biological medicines, and discloses a gingko nano-targeting drug-loaded compound, a preparation method thereof and application of the gingko nano-targeting drug-loaded compound in prevention and treatment of vascular calcification. The invention discloses a ginkgo biloba nano-targeting drug-loaded compound which comprises a ginkgo biloba extract, a nano-carrier and targeting peptide. According to the ginkgo biloba nano-targeting drug-loaded compound provided by the invention, the ginkgo biloba extract is combined with targeting peptide (such as hydroxyapatite binding peptide), so that the ginkgo biloba nano-targeting drug-loaded compound has the capacity of targeting vascular calcification, and the purpose of targeted therapy is achieved. Experimental research proves that for high-phosphorus-induced calcified male mice and HASC-induced calcification models, the gingko nano-targeting drug-loaded compound provided by the invention can effectively relieve vascular calcification, has relatively high safety and is expected to be applied to prevention and treatment of vascular calcification diseases. The invention provides a new thought and prevention and treatment direction for treating vascular calcification.

Use of a p55gamma protein or an encoding gene thereof as a target in the preparation of a drug for preventing and / or treating vascular calcification is provided, belonging to the technical field of vascular calcification prevention and treatment. The use of the p55gamma protein or the encoding gene thereof as the target in the preparation of the drug for preventing and / or treating the vascular calcification is proposed for the first time, and the p55gamma protein affects the vascular calcification by regulating phosphorylation of Yes-associated protein (YAP). It is proposed for the first time that the vascular calcification can be prevented and / or treated by overexpressing p55gamma gene or increasing the activity of the p55gamma protein.

The invention relates to the field of in-vitro diagnostic reagents, in particular to application of a reagent for detecting ACVR2b in preparation of a chronic kidney disease vascular calcification diagnostic kit. It is found for the first time that the expression quantity of ACVR2b is remarkably associated with chronic kidney disease vascular calcification. Therefore, the expression quantity of the ACVR2b can be used for screening the vascular calcification of the chronic kidney disease. On the basis, the invention provides application of a reagent for detecting ACVR2b in preparation of a chronic kidney disease vascular calcification diagnostic kit, and the reagent has a good application prospect.

The invention discloses a method for promoting fusion of macrophages and increasing the content of phosphatidic acid in the macrophages and application of the method, and belongs to the technical field of biomedicine. In order to provide a method for effectively treating vascular calcification, an in-vitro cell experiment proves that the combination of a sound-sensitive agent and low-frequency low-intensity ultrasound can promote M1 type macrophages to be fused into multinuclear osteoclast-like cells and can improve the content of PA in the M1 type macrophages; the sound-sensitive agent is combined with low-frequency low-intensity ultrasound, so that mouse aortic smooth muscle cell calcification can be relieved by increasing the PA content in M1 type macrophages; a mouse in-vivo experiment further proves that the content of PA in an early calcification region of the aorta root of the mouse can be increased by combining the sound-sensitive agent with low-frequency and low-intensity ultrasonic treatment, so that aortic atherosclerotic calcification of the mouse is relieved. The invention provides a new idea for the treatment of vascular calcification.

This invention provides a polypeptide for treating vascular calcification, belonging to the field of biotechnology. By analyzing lncRNA sequencing results from patients with chronic kidney disease exhibiting varying degrees of vascular calcification, this invention reveals for the first time a long non-coding RNA (lncRNA)—LINK-A—highly expressed in these patients. Furthermore, it confirms that LINK-A endogenously expresses a 40-amino acid-residue polypeptide—PKM2-associated polypeptide (PKM2AP)—in its second ORF. Subsequently, in vitro and in vivo experiments validated the important role of this polypeptide in inhibiting vascular calcification. This invention not only provides a novel target (LINK-A) for vascular calcification but also offers a potential drug (PKM2AP) for treating vascular calcification.

A microporous electrode for disruption treatment of vascular calcification, comprising an outer balloon strip (1). A conductive tube (2) penetrates and is connected to an interior of the outer balloon strip (1). A side surface of the conductive tube (2) is provided with a sealing ring seat (32), and the sealing ring seat (32) is fixedly connected to the outer balloon strip (1). The side surface of the conductive tube (2) is provided with a top liquid inlet hole (10), and the top liquid inlet hole (10) is located on the side surface of the internal conductive tube (2) of the outer balloon strip (1); a bottom liquid inlet hole (11) is provided on the side surface of the conductive tube. By enabling a flow of a liquid capable of generating a discharge medium inside the outer balloon strip (1) to be unhindered by a liquid level height, the normal use of the microporous electrode in the disruption treatment of vascular calcification is ensured.

The present invention belongs to the field of biomedicine and specifically relates to the use of plant-derived nanoparticles in the preparation of drugs for the prevention and treatment of vascular calcification. Experimental studies have confirmed that the grapefruit-derived nanoparticles provided by the present invention can effectively alleviate vascular calcification in mouse vascular smooth muscle cells induced by high phosphorus and in mouse vascular calcification models induced by high vitamin D3. Furthermore, the nanoparticles exhibit no significant changes in particle size or membrane potential after prolonged storage, nor do they cause damage to the mouse's major organs (heart, liver, spleen, lungs, and kidneys). These nanoparticles exhibit high stability and good safety, and are expected to be applied in the prevention and treatment of vascular calcification, providing a new approach and improved prevention and treatment strategy for vascular calcification.

This invention discloses a medical image segmentation method for urinary stones based on region connectivity, belonging to the field of medical image processing technology, to solve the problems of high-density bone interference and topological fragmentation in stone segmentation. First, a piecewise weighted mapping function is constructed to adaptively adjust the window width and perform anisotropic filtering on the image, generating a bone suppression feature map. Then, a maximum stable extremum region algorithm combined with anatomical priors is used to extract high-confidence seed points. A fast traversal algorithm is executed using a constructed gradient resistance field to detect geodesic temporal field abrupt changes to define boundaries, generating a simply connected mask. Finally, three-dimensional dense morphology and texture consistency features are fused for weighted discrimination to remove vascular calcification artifacts. This invention ensures the topological connectivity and high accuracy of the segmentation results.

The catheter system 100 includes a power source 124, a controller 123, and a light guide 122. The power source 124 generates a plurality of energy pulses 242B, 342B. The controller 123 controls the power source 124 so that the plurality of energy pulses 242B, 342A-B cooperate to generate composite energy pulses 348A-B, 448A-C, 548A-F having a composite pulse shape. The light guide 122 receives the composite energy pulses 348A-B, 448A-C, 548A-F. The light guide 122 radiates optical energy away from the light guide 122 to generate plasma pulses 246A-B, 346A-B away from the light guide 122. The power source 124 can be a laser, and the light guide 122 can be an optical fiber. Each of the energy pulses 242B, 342A-B has a pulse width, and the energy pulses 242B, 342A-B are added together such that the resulting energy pulse 348A-B, 448A-C, 548A-F has a pulse width longer than the pulse width of any of the energy pulses 242B, 342A-B. The at least two energy pulses 242B, 342A-B can have the same wavelength or different wavelengths.

The invention discloses a use of roxburghii polysaccharide for preparing a drug for resisting vascular calcification. Experimental results show that the roxburghii polysaccharide in the invention has an effect of resisting vascular calcification. Therefore, the roxburghii polysaccharide in the invention has the prospect of being prepared into a drug for resisting vascular calcification, treating diseases caused by vascular calcification or diseases accompanied by vascular calcification, and the diseases accompanied by vascular calcification include atherosclerosis, hypertension and diabetic vascular lesions.

The invention belongs to the technical field of bioactive peptides, and particularly relates to tuna arterial globulin enzymolysis polypeptide as well as a preparation method and application thereof. The amino acid sequence of the tuna arterial globulin enzymatic hydrolysis polypeptide comprises any one or a combination of more of CGDRGFFY, MLGMGGGEET and HAFVMIFFM. The invention further discloses a preparation method of the tuna arterial globulin enzymatic hydrolysis polypeptide. The preparation method comprises the specific steps that tuna arterial globules serve as raw materials, and hydrolysis is conducted in a flavourzyme and alkaline protease compounding mode. According to the invention, the tuna arterial ball is used as a raw material to prepare the polypeptide with the ability of inhibiting vascular calcification, tuna resources are fully utilized, the additional value of the waste tuna arterial ball is improved, and a new development thought is provided for production and processing of tuna. The tuna arterial globulin enzymolysis polypeptide prepared by the preparation method disclosed by the invention has a good effect of preventing vascular calcification. The method is simple to operate, high in practicability and easy for industrial production.

The application belongs to the technical field of medical apparatus and specifically discloses an electromagnetic pulse type shock wave balloon and a vascular interventional treatment instrument, the electromagnetic pulse type shock wave balloon comprises a medical balloon and a medical catheter, a micro disc type coil is arranged in the medical balloon, a conductive wire is arranged in the medical catheter, the conductive wire is connected with the micro disc type coil, and a metal patch is arranged on the inner wall or the outer wall of the medical balloon and corresponds to the micro disc type coil; the micro disc type coil is connected with an external power supply through the conductive wire, the external power supply provides pulse current to flow through the micro disc type coil, an alternating magnetic field is excited, the metal patch generates an eddy current in the magnetic field, the eddy current generates a repulsive force in the magnetic field, the metal patch is pushed to move, the metal patch drives the balloon wall surface to expand and contract, and an outward radiation of a shock wave is formed. The electromagnetic pulse type shock wave balloon is convenient to manufacture, low in cost, longer in service life and stable in shock wave energy, and is a novel shock wave balloon for vascular calcification treatment.

This invention discloses a novel method for processing and detecting CBF (vascular calcification inhibitory factor) in human blood. The sample processing steps are as follows: S1, measure the biological sample into sample tube a, add CBF internal standard working solution, 1% SDS solution, and DTT solution with a final concentration of 10 mM; shake in a water bath; add 4 times the volume of cold acetonitrile and shake thoroughly; centrifuge at 4°C; S2, transfer the supernatant from S1 to sample tube b, add 2.22 times the volume of cold acetonitrile, mix thoroughly, and let stand at -20°C; centrifuge at 4°C and discard the supernatant; S3, add 2.5 times the volume of cold acetonitrile from the blood sample and shake gently; centrifuge at 4°C, discard the supernatant, and air dry at room temperature; S4, add 0.1% FA aqueous solution, vortex, and dissolve thoroughly to obtain the sample to be tested. This method uses HPLC-MS / MS technology to perform absolute quantification of CBF in MRM mode.

The present application relates to a kind of discharge detection circuit, method, high voltage generator and blood vessel calcification treatment equipment, discharge detection circuit includes current sampling module and processing module, current sampling module is set to pulse discharge loop, for the current in pulse discharge loop is sampled to obtain sampling voltage;Processing module is connected with current sampling module, for detecting sampling voltage multiple times during one pulse discharge, and when the number of sampling voltage is valid voltage is greater than or equal to preset value, it is determined that the discharge during pulse discharge is effective discharge.The present application can judge the effectiveness of pulse discharge in pulse discharge loop, to judge the reliability of equipment discharge.

The present invention belongs to the field of biomedicine technology, and specifically relates to a sodium thiosulfate drug modified with plant-derived nanoparticles, and its preparation method and application. The present invention relates to a sodium thiosulfate drug modified with plant-derived nanoparticles, which uses plant-derived nanoparticles as carriers to encapsulate sodium thiosulfate. Through distearoylphosphatidylethanolamine-polyethylene glycol-linked polypeptide SP5-52, it has been shown through experiments that STS can be targeted and delivered to vascular calcification lesions, significantly reducing the drug dosage of STS and reducing toxic side effects; it has shown significant anti-vascular calcification effects on mouse vascular smooth muscle cells induced by high-phosphate calcification agents and mouse vascular calcification models induced by high vitamin D3; and the sodium thiosulfate drug modified with plant-derived nanoparticles has good stability and high safety, and has good application prospects in the treatment of vascular calcification.

The invention discloses application of ursolic acid in preparation of a medicine for preventing and treating vascular calcification, relates to the technical field of biological medicines, and finds that ursolic acid can effectively inhibit vascular calcification through experiments and provides a new way for preventing and treating vascular calcification.

The invention relates to the field of in-vitro diagnostic reagents, in particular to application of a reagent for detecting TNN in preparation of a chronic kidney disease vascular calcification diagnostic kit. It is found for the first time that the expression quantity of TNN is remarkably associated with chronic kidney disease vascular calcification. Therefore, the expression quantity of the TNN can be used for screening the vascular calcification of the chronic kidney disease. On the basis, the invention provides application of the TNN detection reagent in preparation of the chronic kidney disease vascular calcification diagnosis kit, and the application prospect is good.

The present application relates to the field of in vitro diagnostic reagents, in particular to the use of reagents for detecting ACVR2b in the preparation of a diagnostic kit for chronic kidney disease vascular calcification, and it is found for the first time that the expression level of ACVR2b is significantly correlated with chronic kidney disease vascular calcification. Therefore, the expression level of ACVR2b can be used for screening of chronic kidney disease vascular calcification. Based on this, the present application provides the use of reagents for detecting ACVR2b in the preparation of a diagnostic kit for chronic kidney disease vascular calcification, which has a good application prospect.

A catheter system (100) for treating a treatment site (106) within or adjacent to a blood vessel (108) includes a power source (124), a light guide (122), and a plasma target (242). In various embodiments, the light guide (122) receives power from the power source (124). The light guide (122) has a distal tip (244), and the light guide (122) emits light energy (243) in a direction away from the distal tip (244). The plasma target (242) is spaced apart from the distal tip (244) of the light guide (122) by a target gap distance (245). The plasma target (242) is configured to receive light energy (243) from the light guide (122) such that plasma bubbles (234) are generated at the plasma target (242). The power source (124) may be a laser, and the light guide (122) may be an optical fiber. The catheter system (100) may also be an inflatable balloon (104) surrounding the distal tip (244) of the light guide (122). The plasma target (242) may have a target surface (1672) that receives the light energy (243) from the light guide (122). The plasma target (242) may be formed from one or more of tungsten, tantalum, platinum, molybdenum, niobium, iridium, magnesium oxide, beryllium oxide, tungsten carbide, titanium nitride, titanium carbonitride, and titanium carbide.